Group 1 - The core point of the announcement is that Luoxin Pharmaceutical Group Co., Ltd. disclosed changes in the equity of its major shareholders, specifically a reduction in shareholding by over 1% [2][4][21] - The major shareholder Fang Xiubao and its concerted actors, including Fang Donghui and Wenzhou Daren Enterprise Management Co., Ltd., have reduced their holdings by 1,595,800 shares, representing 0.15% of the total share capital [2][4] - Following this reduction, the combined shareholding of Fang Xiubao and its concerted actors decreased from 12.10% to 11.96% [2][4] Group 2 - The company held its 27th meeting of the fifth board of directors on August 1, 2025, to discuss various matters, including providing guarantees for its subsidiary [5][6] - The board approved a proposal to provide a guarantee of RMB 20 million for its subsidiary, Luoxin Anruo Weita Pharmaceutical (Chengdu) Co., Ltd., to support its operational needs [6][28] - The guarantee proposal will be submitted to the shareholders' meeting for approval, requiring a two-thirds majority vote [8][18] Group 3 - The company announced the convening of the 2025 Fourth Extraordinary General Meeting of Shareholders on August 18, 2025, to discuss the approved proposals from the board meeting [9][32] - The meeting will be held both in-person and via online voting, allowing shareholders to participate remotely [34][39] - The registration date for shareholders to attend the meeting is set for August 11, 2025 [35][36]

Group 1 - The board of directors of Luoxin Pharmaceutical Group Co., Ltd. held its 27th meeting, which was legally convened and attended by all five directors [1] - The board approved a proposal to provide a guarantee of RMB 20 million for its subsidiary, Luoxin Anruowei Pharmaceutical (Chengdu) Co., Ltd., to support its operational and business expansion needs [1] - The guarantee will be valid for 12 months from the date of approval by the shareholders' meeting [1] Group 2 - The board proposed to convene the fourth extraordinary general meeting of shareholders in 2025 on August 18, 2025, which also received unanimous approval [2] - The proposal for the guarantee and the extraordinary general meeting will require approval from at least two-thirds of the voting rights at the shareholders' meeting [2]

Group 1 - The company announced that its fifth board of directors held the 27th meeting, where it approved a proposal to provide guarantees for its controlling subsidiary [2] - The company also approved a proposal to convene the fourth interim shareholders' meeting for the year 2025 [2]

（文章来源：证券日报） 证券日报网讯 8月1日晚间，罗欣药业发布公告称，公司第五届监事会第二十三次会议审议通过了《关 于为控股子公司提供担保的议案》。 ...

Core Viewpoint - The company, Luoxin Pharmaceutical (002793), announced that it will hold its fourth extraordinary general meeting of shareholders on August 18, 2025, to review a proposal regarding providing guarantees for its controlling subsidiary [1] Group 1 - The extraordinary general meeting is scheduled for August 18, 2025 [1] - The agenda includes a proposal to provide guarantees for a controlling subsidiary [1]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-070 罗欣药业集团股份有限公司 关于为控股子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保 总额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公 司最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司罗欣安若维他药业（成都）有限公司（以下简称 "罗安公司"）人民币 2,000 万元银行授信额度提供担保。具体担保金额、担保 期限等事项以各方后续签署的担保协议或担保文件约定为准。上述担保额度有效 期限自股东大会审议通过之日起 12 个月。 公司于 2025 年 8 月 1 日召开第五届董事会第二十七次会议及第五届监事会 第二十三次会议，审议通过了《关于为控股子公司提供担保的议案》。根据《深 圳证券交易所股票上市规则》《罗欣药业集团股份有限公司章程》等的相关规定， ...

证券代码：002793 证券简称：罗欣药业 公告编号：2025-071 罗欣药业集团股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司"）于2025年8月1日召开的第 五届董事会第二十七次会议，审议通过了《关于召开2025年第四次临时股东大会 的议案》，现将会议有关事项通知如下： 一、召开会议基本情况 1、股东大会届次：2025年第四次临时股东大会 2、股东大会的召集人：本次股东大会由公司董事会召集，经公司第五届董 事会第二十七次会议审议通过。 3、会议召开的合法、合规性：本次股东大会会议的召集、召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议时间：2025年8月18日（星期一）下午2:00 （2）网络投票时间：2025年8月18日 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年8月18日的 交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-069 罗欣药业集团股份有限公司 第五届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、备查文件 1、第五届监事会第二十三次会议决议。 特此公告。 罗欣药业集团股份有限公司监事会 二、监事会会议审议情况 （一）审议通过《关于为控股子公司提供担保的议案》 经审核，监事会认为：本次公司为控股子公司提供担保的事项有利于公司的 经营发展，符合公司整体利益。决策程序符合有关法律法规、规范性文件及《公 司章程》等的规定，不存在损害公司和中小股东利益的情形。具体内容详见同日 刊登于巨潮资讯网（http://www.cninfo.com.cn）、《上海证券报》的《关于为控股子 公司提供担保的公告》。 表决结果：3 票同意、0 票反对、0 票弃权。 本议案尚需提交股东大会审议，并经出席股东大会的股东（包括股东代理人） 所持表决权的三分之二以上（含）通过。 一、监事会会议召开情况 2025 年 8 月 1 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届监事会第二十三次会议在 ...

罗欣药业集团股份有限公司 第五届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 8 月 1 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届董事会第二十七次会议在山东省临沂高新技术产业开发区罗七路管理中心三 楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合 的方式召开。会议通知已于 2025 年 7 月 29 日以电话、专人送达、电子邮件等方 式发出。本次会议应出席董事 5 名，实际出席董事 5 名，公司监事、董事会秘书 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》等法律法规、规范性文件和《罗欣药业集团股份有限公司 章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于为控股子公司提供担保的议案》 证券代码：002793 股票简称：罗欣药业 公告编号：2025-068 表决结果：5 票同意、0 票反对、0 票弃权。 上述议案已经公司董事会审计委员会全票审议通过。 1 表决结果：5 票同意、0 票反对、 ...

Core Viewpoint - The stock price of Luoxin Pharmaceutical (002793) experienced a significant increase, closing at 6.5 yuan with a 6.04% rise on July 31, 2025, following a series of trading days with abnormal fluctuations [1] Group 1: Stock Performance - The stock reached a yearly high of 6.74 yuan, with a turnover rate of 16.05% and a trading volume exceeding 1.142 billion yuan [1] - The stock was flagged for abnormal trading as its cumulative price deviation exceeded 20% over three consecutive trading days [1][2] Group 2: Financial Performance and Forecast - Luoxin Pharmaceutical has faced continuous losses for three years, with revenues declining from 35.88 billion yuan in 2022 to 26.47 billion yuan in 2024, compared to a peak of 75.89 billion yuan in 2019 [9] - The company reported net losses of 12.26 billion yuan, 6.61 billion yuan, and 9.65 billion yuan over the same period, totaling 28.52 billion yuan in losses, surpassing previous six years' profits of 16.89 billion yuan [9] - The latest earnings forecast for the first half of 2025 indicates a potential net profit of 15 to 20 million yuan, with a basic earnings per share of 0.01 to 0.02 yuan [10] Group 3: Shareholder Changes and Transactions - A significant change in the shareholder structure occurred with the transfer of 5% of shares to Shanghai Zhongjue Private Fund Management Co., Ltd., at a price of 2.03 billion yuan, reflecting a 70% premium over the market price [6] - The transaction resulted in Zhongjue Fund becoming the third-largest shareholder, holding 5% of the shares, while the first and second largest shareholders hold 21.79% and 9.22% respectively [6] Group 4: Asset Transfer and Payment Issues - Luoxin Pharmaceutical has not received the third installment of the payment for the transfer of a 70% stake in its subsidiary, which was valued at 4.15 billion yuan, with only 2.87 billion yuan received to date [3][5] - The performance of the subsidiary, now named Shanghai Luoxin Pharmaceutical (Shandong) Co., Ltd., fell significantly short of its revenue and profit commitments, achieving only 18.32 billion yuan in revenue and 10.69 million yuan in net profit for 2024, which is 31.74% of the promised figures [4][5][11]